GlassScriptPhysician profile
Mark A Mcclanahan
NPI 1093840811
$3,679.62
in general payments reported to CMS, 2019-2025
32 companies · $73.73 in 2025
The $73.73 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,211 · 2020: $628 · 2021: $618 · 2022: $341 · 2023: $319 · 2024: $489 · 2025: $73.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $861 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $861.35 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $674.20 | 2020-2021 | |
| Valeritas, INC. | $548.38 | 2019 | |
| Lilly USA, LLC | $257.71 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $216.00 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.81 | 2019-2023 | Tradjenta |
| Dexcom, INC. | $201.15 | 2019-2023 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $187.01 | 2021-2023 | Tepezza |
| Sanofi-Aventis U.S. LLC | $185.90 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $143.54 | 2019-2020 | |
| Intuity Medical INC | $124.98 | 2022 | |
| Abbott Laboratories | $99.33 | 2021-2024 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $85.02 | 2020-2023 | Gvoke Hypopen |
| Novo Nordisk INC | $61.97 | 2019-2024 | Rybelsus, Ozempic |
| Tandem Diabetes Care, INC. | $59.25 | 2020-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $53.79 | 2023-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $52.53 | 2023 | Ilet Bionic Pancreas |
| Insulet Corporation | $50.78 | 2019-2024 | Omnipod |
| Amgen INC. | $49.62 | 2019-2025 | Repatha, Tepezza |
| Ibsa Pharma INC. | $46.98 | 2021-2025 | Tirosint, Flector, Licart |
| Novartis Pharmaceuticals Corporation | $46.53 | 2024 | |
| Amneal Pharmaceuticals LLC | $40.74 | 2020-2024 | Unithroid |
| Cequr Corporation | $39.15 | 2023-2024 | Cequr Simplicity |
| Mannkind Corporation | $35.06 | 2024 | |
| Radius Health, INC. | $34.37 | 2024 | Tymlos |
| Corcept Therapeutics | $27.95 | 2024 | Korlym |
| Kyowa Kirin, INC. | $25.56 | 2023 | |
| Averitas Pharma INC. | $22.70 | 2023 | Qutenza |
| Esperion Therapeutics, INC. | $22.64 | 2021 | |
| Medtronic, INC. | $20.78 | 2024 | Minimed 780g |
| Antares Pharma, INC. | $19.30 | 2020 | |
| Janssen Pharmaceuticals, INC | $16.35 | 2020 | |
| Amarin Pharma, INC. | $15.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mcclanahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.